灵芝提取物β-1,3-葡聚糖含量测定及多糖成分分析

采用酶法试剂盒检测法和苯胺蓝荧光检测法对不同结构多糖中β-葡聚糖含量进行测定,结果表明,两种方法对高纯度β-1,3/1,6-葡聚糖的含量检测均较为准确,但含有葡萄糖的杂多糖和多分支连接的β-葡聚糖均会对酶法试剂盒检测产生干扰,苯胺蓝荧光法检测β-1,3-葡聚糖专一性较好。通过比较不同灵芝提取物中β-1,3-葡聚糖的含量和得率可知,热水提取物和KOH提取物中β-1,3-葡聚糖的含量较高,分别为20.52%和45.86%,β-1,3-葡聚糖得率分别为0.27%和1.27%,占β-1,3-葡聚糖总提取得率的88%。HPSEC分析结果显示不同提取物中多糖的分子量分布不同,热水提取物中主要包含2个组分,分子量分别为2.835×10~6Da和9.587×10~4Da,KOH提取物中主要包含分子量分布在1×10~5–1×10~6Da范围内的3个组分。各提取物中多糖的单糖组成均以葡萄糖为主,水提多糖中含有少量半乳糖,酸碱提取多糖中含有少量木糖和甘露糖。本研究结果显示,分步提取中沸水和KOH碱溶液提取β-1,3-葡聚糖效率较高。     

灵芝菌丝液体深层发酵产β-葡聚糖的培养基优化

灵芝β-葡聚糖是灵芝多糖中生物活性较高的一类多糖。通过单因素试验确定影响灵芝液体发酵β-葡聚糖的3个关键参数为:可溶性淀粉(A)40g/L,蛋白胨(B)8g/L,K2HPO4(C)1.5g/L。在此基础上,采用Box-Behnken设计及响应面分析法对各参数及其交互作用进行了研究。结果显示,3因素及AB、AC的交互作用对β-葡聚糖得率的影响均为极显著水平(P0.01)。建立的预测灵芝β-葡聚糖发酵的多项式模型为:Yβ-葡聚糖=8.68+0.22A-0.13B+0.096C+0.13AB+0.16AC+0.045BC-1.17A2-0.81B2-1.06C2。经响应面最优分析,获得3个关键因素的最佳水平为:可溶性淀粉40.47g/L,蛋白胨7.86g/L,K2HPO4 1.53g/L,在该条件下,灵芝菌体β-葡聚糖得率可达8.68mg/g。     

灵芝-黄芪双向发酵菌质多糖的分离纯化及生物活性研究

本文旨在探究灵芝-黄芪双向固体发酵体系对灵芝多糖生物活性的增效作用。分别以灵芝-黄芪双向发酵菌质和未添加黄芪的灵芝菌发酵菌质为原材料提取多糖,采用热水浸提和离子交换色谱对粗多糖进行分离,得到PG-1和PG-2,添加黄芪发酵的菌质多糖中的PG-1组分相较于未添加黄芪发酵的菌质多糖中的PG-2组分增加了325%的产量。对PG-1和PG-2进行初步的结构鉴定和免疫活性、抗肿瘤活性的研究。运用排阻色谱法测定其分子量,高效液相色谱、紫外光谱和红外光谱等方法分析其单糖组成、官能团、糖苷键构型以及糖分子链链型。PG-1和PG-2都由葡萄糖醛酸、葡萄糖、木糖和阿拉伯糖4种组成,单糖组分摩尔比分别为12∶58∶21∶9和16∶41∶32∶11。分子量分别为9.2×10~4和8.9×10~4。PG-1和PG-2均由β-糖苷键连接,二者糖链间有—O—连接。PG-1和PG-2均是具有三螺旋空间构象的分子量相对均一的多糖。体外细胞实验结果显示:加入PG-1和PG-2后,巨噬细胞的增殖作用、巨噬细胞对中性红的吞噬作用、巨噬细胞的保护作用和对肿瘤细胞增殖的抑制作用都显著地提高。在细胞实验中,PG-1显示出比PG-2更强的免疫增强活性和对肿瘤细胞增殖的抑制作用,说明添加黄芪促进了灵芝菌质多糖的分泌,使灵芝多糖的免疫增强活性和抗肿瘤活性增强。     

外源物质对灵芝多糖和β-葡聚糖发酵的影响

研究了14种外源物质（化合物）对灵芝细胞生长和发酵合成多糖和β-葡聚糖的影响。结果表明,连翘水提物（3g/L）对灵芝细胞生长具有显著促进作用;薏苡仁酯（3g/L）对灵芝胞内多糖和β-葡聚糖的合成均具有促进作用;而桔梗水提物、硝酸铈铵、硝酸镨、茉莉酸甲酯和硝普钠对灵芝细胞生长和产物合成均具有抑制作用。进一步通过Box-Behnken试验设计和响应面法分析,建立了添加薏苡仁酯发酵产β-葡聚糖的二次多项式模型,经分析得到产β-葡聚糖的最优条件为：薏苡仁酯添加量10.5g/L、接种量16%、添加时间第88小时、发酵初始pH 7.00。在此条件下获得β-葡聚糖的产量可达(40.67±8.43)mg/L,与未添加薏苡仁酯的对照组相比,提高了41.86%;多糖产量为(0.99±0.21)g/L,与对照组相比,提高了31.99%。结果提示所得添加薏苡仁酯的优化条件可定向诱导灵芝β-葡聚糖的合成,同时也表明在灵芝液体发酵体系中添加薏苡仁酯发酵产多糖和β-葡聚糖具有一定的实用价值。     

真菌多相结构的化学修饰

真菌多糖因具有独特的分子结构,一般都具有促进免疫、抑制肿瘤的活性,但这种活性随真菌种类及其产生的多糖种类不同而差异较大;另外真菌多糖都具有较大的分子量,水中溶解性较差,这为真菌多糖的实际应用造成了一定的困难．对某些真菌多糖的结构进行必要的化学修饰,不仅可增强其促进免疫和抗肿瘤活性,而且水溶性也大大地提高。茯苓多糖是β-1,6-葡糖链分支的β-1,3-葡聚糖,没有抗肿瘤活性,经高碘酸氧化、Smith降解、硼氢化钠还原可得较小分支的中间产物,再经酸水解去除分支得到直链多糖,即茯苓新糖。茯苓新糖和中间产物均具有很…     

小菜蛾幼虫血淋巴中β-1,3-葡聚糖结合蛋白的分离及其对根虫瘟霉侵染的免疫活性

用亲和沉淀法从小菜蛾(Plutella xylostella)幼虫血淋巴中分离获得2种β-1,3-葡聚糖结合蛋白,分子质量分别为75.9 ku和83.2 ku,主要存在于幼虫血浆中,但血细胞中未检出.研究表明,β-1,3-葡聚糖结合蛋白能特异性地识别β-1,3-葡聚糖,并显著激活幼虫血淋巴中的酚氧化酶原（ProPO）,与昆布多糖共存时所激活的酚氧化酶（PO）活性显著高于两者单独存在时的PO活性.与4株根虫瘟霉(Zoophthora radicans)菌丝裂解液共存时,β-1,3-葡聚糖结合蛋白能激活幼虫血淋巴中的ProPO,使PO活力显著高于该菌原生质体裂解液所激活的PO活性.显然,β-1,3-葡聚糖结合蛋白只有特异性地识别根虫瘟霉细胞壁中的β-1,3-葡聚糖后才能激活幼虫血淋巴中的ProPO,表明虫霉原生质体可逃避寄主免疫反应.此外,β-1,3-葡聚糖结合蛋白对不同菌株所激活的PO活性存在差异,各菌株所激活的PO活性由高到低依次为：ARSEF1342＞ARSEF2699＞F99101＞ARSEF1100,这与各菌株对小菜蛾的毒力强弱相一致,即菌株逃避寄主免疫识别的能力与其毒力相关.     

活化型高分子量激肽原潜在的抗肿瘤作用及其分子机制

高分子量激肽原是血浆中一种多功能的糖蛋白,与血液凝固的启动、 补体反应及炎症发生等有密切关系.新近的研究显示,活化型高分子量激肽原 具有潜在的抗肿瘤作用.本文综述活化型高分子量激肽原在细胞粘附和血管 生成中发挥的抑制作用及其活性区域,抑制细胞迁移、增殖并诱导细胞凋亡 的作用,及其在细胞表面的作用位点和分子机制.活化型高分子量激肽原作用 机制,包括抑制细胞DNA的从头合成,使细胞周期蛋白D1表达下降,以及通过 影响细胞内信号通路发挥其活性效应等.深入研究活化型高分子量激肽原在 细胞表面作用的信号转导通路可能是今后抗肿瘤研究途径之一.     

灵芝子实体、菌丝体及孢子粉中多糖成分差异比较研究

为探讨灵芝子实体、菌丝体和孢子粉3种材料中多糖成分的差异,分别运用苯酚硫酸法进行多糖含量测定,运用离子色谱分析其酸水解后单糖组成,并运用HPLC分析各多糖图谱及经α-淀粉酶和β-1,3-葡聚糖酶处理后HPLC图谱的变化,结果发现,灵芝菌丝体中多糖含量最高,达到3.81%,孢子粉多糖含量为1.8%,灵芝子实体中多糖含量最低,仅为0.59%;水解后的单糖组成及摩尔比也有差异,子实体的单糖主要为葡萄糖和半乳糖,菌丝体和孢子粉的单糖主要为葡萄糖;HPLC图谱显示3种多糖出峰位置和分子量也不同,酶解效果表明多糖结构也相差较大。各样品多糖对小鼠巨噬细胞RAW264.7释放NO的产量的影响上,菌丝体与子实体多糖都表现出了很好的活性,而孢子粉多糖却呈现出较低活性。实验结果表明灵芝子实体、菌丝体和孢子粉3种材料的多糖成分差异大,在医药保健品使用中应区分使用。     

灰树花活性多糖构效关系研究进展

灰树花是一种珍贵的食药用菌,具有降血糖、抗肿瘤、免疫调节和抗病毒等多种生物活性。灰树花多糖是其主要的活性成分,多糖的生物活性与多糖的结构密切相关。本文综述了从20世纪80年代起国内外已报道的灰树花活性多糖的结构表征。部分研究认为多糖的降血糖活性可能与β-1,6-葡聚糖主链化学结构相关,而灰树花多糖结构为β-1,6主链或β-1,3主链葡聚糖时具有较好的抗肿瘤活性。然而多糖结构异常复杂,精细结构的解析困难,导致目前灰树花多糖结构表征一般止步于单糖组成、分子量、糖苷键类型、分支结构和粗略分子链构象,但二维核磁(two dimensional nuclear magnetic resonance,2D-NMR)和高分辨质谱联用等技术的发展将有助于解开灰树花多糖构效关系,并为灰树花活性多糖的开发利用提供理论依据。     

黄粉虫β-1,3-葡聚糖识别蛋白的分离纯化及部分生物学功能

采用中性盐沉淀、凝胶层析等常规方法纯化黄粉虫Tenebrio molitor血淋巴中的β-1,3-葡聚糖识别蛋白,并对其在酚氧化酶原激活系统中的作用进行了初步的研究。结果表明:黄粉虫血淋巴的β-1,3-葡聚糖识别蛋白的分子量约为70 kDa,主要分布于血浆中。纯化的β-1,3-葡聚糖识别蛋白只能特异性地识别β-1,3-葡聚糖而不能识别肽聚糖。在β-1,3- 葡聚糖所诱导的酚氧化酶原的激活过程中,随着酚氧化酶原激活程度的提高,内源性β-1,3-葡聚糖识别蛋白的含量逐渐减少。抗β-1,3-葡聚糖识别蛋白多克隆抗体对黄粉虫血淋巴中由β-1,3-葡聚糖所诱导的酚氧化酶活性起抑制作用,且该抑制作用呈现一种剂量依赖性的趋势。上述结果有助于深入了解β-1,3-葡聚糖对黄粉虫血淋巴酚氧化酶原激活系统的激活作用。     

Mechanisms of the Anticancer Action of Ganoderma lucidum (Leyss. ex Fr.) Karst.: A New Understanding

Ganoderma lucidum (Leyss. ex Fr.) Karst., a medicinal fungus called "Lingzhi" in China, has been used in traditional Chinese medicine in China for the prevention and treatment of various types of diseases, such as cancer, hepatopathy, arthritis, hypertension, neurasthenia, and chronic hepatitis. It is clear that the anticancer activity of G. lucidum is mainly due to polysaccharides and/or triterpenoids of the fungus. However, until now, the mechanism of the anticancer action of G. lucidum has not been well understood and, previously, the activation of the immune response of the host was widely considered to be the only mechanism by which G. lucidum prevented and/or treated cancer. However, recent studies reviewed in the present paper have shown that the potential mechanisms of anticancer action include not only the activation of the immune response of the host, but also the induction of cell differentiation, the induction of Phase Ⅱ-metabolizing enzymes, the inhibition of angiogenesis, and the inhibition of the expression of the urokinase-type plasminogen activator (uPA) and the uPA receptor in cancer cells. To further elucidate the mechanisms of action of G. lucidum, more in vivo tests and randomized controlled clinical trials should be carried out, and the molecular mechanisms should be studied intensively. Additionally, whether the anticancer compounds in G. lucidum act synergistically or independently should be further studied.     

Mechanisms of the Anticancer Action of Ganoderma lucidum （Leyss. ex Fr.） Karst.： A New Understanding

Ganoderma lucidum (Leyss. ex Fr.) Karst., a medicinal fungus called “Lingzhi” in China, has been used in traditional Chinese medicine in China for the prevention and treatment of various types of diseases, such as cancer, hepatopathy, arthritis, hypertension, neurasthenia, and chronic hepatitis. It is clear that the anticancer activity of G. lucidum is mainly due to polysaccharides and/or triterpenoids of the fungus. However, until now, the mechanism of the anticancer action of G. lucidum has not been well understood and, previously, the activation of the immune response of the host was widely considered to be the only mechanism by which G. lucidum prevented and/or treated cancer. However, recent studies reviewed in the present paper have shown that the potential mechanisms of anticancer action include not only the activation of the immune response of the host, but also the induction of cell differentiation, the induction of Phase Ⅱ-metabolizing enzymes, the inhibition of angiogenesis, and the inhibition of the expression of the urokinase-type plasminogen activator (uPA) and the uPA receptor in cancer cells. To further elucidate the mechanisms of action of G. lucidum, more in vivo tests and randomized controlled clinical trials should be carried out, and the molecular mechanisms should be studied intensively. Additionally, whether the anticancer compounds in G. lucidum act synergistically or independently should be further studied.     

Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1

The polysaccharides of Ganoderma lucidum (Reishi) possess immunomodulation activities; however, their mode of molecular action in regulating each cellular subset in the immune system is still not clear. Here, we investigate the function of the main polysaccharide fraction of Reishi (Reishi-F3) in B lymphocyte activation/differentiation. We find that Reishi-F3 causes mouse splenic B cell activation and differentiation to IgM-secreting plasma cells, and the process depends on Reishi-F3-mediated induction of Blimp-1, a master regulator capable of triggering the changes of a cascade of gene expression during plasmacytic differentiation. In human peripheral B lymphocytes, although Reishi-F3 fails to induce their activation, it is able to enhance antibody secretion, which is associated with Blimp-1 mRNA induction. The function of Reishi-F3 depends on the Toll-like receptors TLR4/TLR2 as neutralizing antibodies against TLR4/TLR2 block Reishi-F3-mediated induction of Blimp-1 mRNA and Ig secretion. We have shown that interaction of Reishi-F3 with TLR4/TLR2 followed by signaling through p38 MAPK is involved in the induction of Blimp-1 mRNA, whereas signaling through ERK, p38 MAPK, JNK, and IKK complex is involved in Reishi-F3-mediated Ig secretion. Furthermore, the differential mechanism of Reishi-F3 in mouse and human B cell activation is probably due to the presence of Blimp-1 regulatory site in human CD86 promoter. These results establish the signaling and molecular mechanisms of Reishi-F3 on promoting antibody secretion.     

Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C,activating mitogen-activated protein kinases and G2-phase cell cycle arrest

The medicinal mushroom Ganoderma lucidum (G. lucidum) has been used in the Orient for the prevention and treatment of various diseases including cancer. Except for the immune enhancing properties of its polysaccharide constituent, very little is known about the anticancer activity of another major constituent, triterpenes. In this report, we studied the anticancer mechanism of triterpene-enriched extracts from G. lucidum. The triterpene-enriched fraction, WEES-G6, was prepared from mycelia of G. lucidum by sequential hot water extraction, removal of ethanol-insoluble polysaccharides and then gel-filtration chromatography. We found that WEES-G6 inhibited growth of human hepatoma Huh-7 cells, but not Chang liver cells, a normal human liver cell line. Treatment with WEES-G6 caused a rapid decrease in the activity of cell growth regulative protein, PKC, and the activation of JNK and p38 MAP kinases. The changes in these molecules resulted in a prolonged G2 cell cycle phase and strong growth inhibition. None of these effects were seen in the normal liver cells. Our findings suggest that the triterpenes contained in G. lucidum are potential anticancer agents.     

Profiling Carbohydrate-Receptor Interaction with Recombinant Innate Immunity Receptor-Fc Fusion Proteins

The recognition of bacteria, viruses, fungi, and other microbes is controlled by host immune cells, which are equipped with many innate immunity receptors, such as Toll-like receptors, C-type lectin receptors, and immunoglobulin-like receptors. Our studies indicate that the immune modulating properties of many herbal drugs, for instance, the medicinal fungus Reishi (Ganoderma lucidum) and Cordyceps sinensis, could be attributed to their polysaccharide components. These polysaccharides specifically interact with and activate surface receptors involved in innate immunity. However, due to the complexity of polysaccharides and their various sources from medicinal fungi, quantitative analysis of medicinal polysaccharide extracts with regard to their functions represents a major challenge. To profile carbohydrate-immune receptor interactions, the extracellular domains of 17 receptors were cloned as Fc-fusion proteins, such that their interactions with immobilized polysaccharides could be probed in an enzyme-linked immunosorbent assay. The results show that several innate immune receptors, including Dectin-1, DC-SIGN, Langerin, Kupffer cell receptor, macrophage mannose receptor, TLR2, and TLR4, interact with the polysaccharide extracts from G. lucidum (GLPS). This analysis revealed distinct polysaccharide profiles from different sources of medicinal fungi, and the innate immune receptor-based enzyme-linked immunosorbent assay described here can serve as a high-throughput profiling method for the characterization and quality control of medicinal polysaccharides. It also provides a means to dissect the molecular mechanism of medicinal polysaccharide-induced immunomodulation events.     

5个不同灵芝种菌丝体多糖理化性质及免疫活性研究

对灵芝属G.lucidum,G.tsugae,G.oerstedii,G.resinaceum,G.subamboinens5个不同种用同一条件进行了液体发酵培养、多糖提取、理化性质及免疫活性的分析。结果表明,5种灵芝的菌丝体多糖得率相差较大,以G.oerstedii最高,但各多糖提取物分子量分布相似,单糖组成均以葡萄糖为主,并含半乳糖、甘露糖、盐酸氨基葡萄糖、岩藻糖。5种多糖提取物均能显著增强小鼠巨噬细胞Raw264.7吞噬作用、释放NO,但以G.subamboinens菌丝体多糖提取物的活性最强。这些多糖提取物还均能促进小鼠脾细胞的增殖,并对ConA诱导的淋巴细胞增殖有抑制作用。研究表明灵芝属内其他3个物种的菌丝体多糖提取物理化特征与G.lucidum和G.tsugae接近,并同样具有免疫调节作用。     

A bioassay for determination of lipopolysaccharide in environmental samples

Although the limulus amebocyte lysate (LAL) assay is widely used to determine the concentration of LPS in biological samples, it is known to be susceptible to interference caused by substances of non-bacterial origin. In particular, polysaccharides such as β-glucans and pectic polysaccharides from fungi or plants, respectively, were shown to give higher LPS readings than were actually present in the sample. Here, we describe an assay for the determination of LPS in biological samples based on the stimulation of TLR4/MD2/CD14 transfected HEK293 cells which dose dependently release IL-8 upon stimulation with increasing concentrations of highly purified Escherichia coli LPS. The resulting standard curve is used to determine the LPS concentration in unknown samples. We show that the outcome of the LPS stimulation is not affected by the presence of β-glucans or other environmental substances found in dust extracts. Although, we present evidence that the LPS concentration measured with the kinetic chromogenic LAL test correlates with data from the TLR4 assay, the LAL test displays higher LPS readings. We conclude that the described TLR4 assay is a reliable alternative to assess the concentration of LPS in environmental samples without being influenced by polysaccharides such as β-glucans and other environmental substances found in dust extracts.     

Mechanism of the antiulcerogenic effect of Ganoderma lucidum polysaccharides on indomethacin-induced lesions in the rat

Many cytokines, in particular tumor necrosis factor (TNF)-alpha have been known to play an important role in the pathogenesis of gastric mucosal lesions caused by various factors such as drugs and Helicobacter pylori infection. Our previous studies have shown that the polysaccharide fractions isolated from the fruiting bodies of Ganoderma lucidum (GLPS) prevented indomethacin- and acetic acid-induced gastric mucosal lesions in the rat. However, the mechanisms remain unclear. This study aimed to investigate whether GLPS had a direct mucosal healing effect in the indomethacin-treated rat, and to explore the possible mechanisms by determining the gastric mucosal mRNA and protein levels of TNF-alpha and ornithine decarboxylase (ODC) activity. In addition, the effects of GLPS on the cellular proliferation, ODC and c-Myc protein expression and mucus synthesis in the rat gastric cell culture (RGM-1) were examined. The present study demonstrated that GLPS at 250 and 500 mg/kg by intragastric input caused ulcer-healing effect in the rat; this was accompanied with a significant suppression of TNF-alpha gene expression, but with an increased ODC activity. In RGM-1 cells, GLPS at 0.05, 0.25 and 1.0 mg/ml significantly enhanced [3H]thymidine incorporation and ODC activity in a concentration-dependent manner. However, these effects were abrogated by the addition of the ODC inhibitor, DL-alpha-difluoromethyl-ornithine (DFMO). GLPS at 0.25-1.0 mg/ml also increased mucus synthesis, as indicated by the increased D-[6-3H]glucosamine incorporation in RGM-1 cells. Furthermore, GLPS at 0.05-1.0 mg/ml increased the c-Myc protein expression. These findings indicated that GLPS produced a mucosal healing effect in the rat model, perhaps due partly to the suppression of TNF-alpha and induction of c-myc and ODC gene.     

Uropathogenic Escherichia coli as a model of host-parasite interaction

Resistance to mucosal infection varies greatly in the population, but the molecular basis of disease susceptibility is often unknown. Studies of host-pathogen infections are helpful to identify virulence factors, which characterise disease isolates, and successful defence strategies of hosts that resist infection. In the urinary tract infection (UTI) model, we have identified crucial steps in the pathogen-activated innate host response, and studied the genetic control of these activation steps. Furthermore, genetic variation in the innate host-response defence is investigated as a basis of disease susceptibility. The Toll-like receptor 4 (TLR4) controls initial mucosal response to uropathogenic Escherichia coli (UPEC). Bacterial TLR4 activation in epithelial cells leads to chemokine secretion and neutrophil recruitment and TLR4 mutant mice develop an asymptomatic carrier state. The chemokine receptor CXCR1 determines the efficiency of neutrophil migration and activation, and thus of bacterial clearance. CXCR1 mutant mice become bacteremic and develop renal scars and studies in UTI prone children have detected low CXCR1 expression, suggesting that CXCR1 is also essential for human disease susceptibility.